Funding for this research was provided by:
Received: 4 November 2019
Accepted: 5 October 2020
First Online: 14 October 2020
Ethics approval and consent to participate
: The study was approved by the ethical review committee in Münster (2020-609-f-S). All participants of the survey read, understood and accepted the following statement: “The aim of this survey is to gain views and experiences of patients diagnosed with ATTR amyloidosis to provide a better understanding of ATTR patient needs and challenges. Any information that you disclose in this survey will be treated in strict confidence and no answers will be attributable to you as an individual.”
: Not applicable.
: The authors declare that they have no competing interests.